(All times shown as Eastern Standard Time, EST)
| 08:00 – 09:15 | Session V: Gene and Base Editing of/with mRNA | Chair: Melissa Moore |
| 08:00 – 08:25 | Spatial and environmental tuning of genetic information within the cephalopod nervous system by RNA editing | Joshua Rosenthal (MBL Woods Hole) |
| 08:25 – 08:50 | Base Editing and Prime Editing: Chemistry on the Genome Editing Without Double-Strand Breaks | David Liu (Harvard Chemistry) |
| 08:50 – 09:15 | Selective ORgan Targeting (SORT): A strategy for effective tissue specific mRNA delivery and gene editing | Dan Siegwart (UTSW) |
| 09:15 – 09:30 | Break | |
| 09:30 – 11:05 | Session VI: Therapeutics | Chair: Josh Frederick |
| 09:30 – 09:55 | mRNA-Based Approach For Treating Ischemic Heart Disease | Lior Zangi (Mt Sinai) |
| 09:55 – 10:20 | Intratumoral interleukin-12 mRNA therapy promotes TH1 transformation of the tumor microenvironment | Nadia Luheshi (AstraZeneca) |
| 10:20 – 10:35 | Onco-selective Messenger RNAs For Cancer Cell-Specific Protein Expression | Yusuf Erkul (Kernal Biologics) |
| 10:35 – 10:50 | In Vivo Bone Tissue Induction by Collagen-nanohydroxyapatite Matrix Loaded with BMP2/NS1 mRNAs Lipopolyplexes | Chantal Pichon (CNRS Orléans) |
| 10:50 – 11:05 | Intraventricular BDNF mRNA administration prevents ischemic neuronal death with the uptake predominantly by astrocytes | Yuta Fukushima (Tokyo Medical and Dental Univ) |
| 11:05 – 11:30 | Break | |
| 11:30 – 14:45 | Session VII: Pandemic Responses/COVID-19 | Chair: Norbert Pardi |
| 11:30 – 11:50 | mRNA platform advances and COVID-19 candidate vaccines | Nicholas Jackson (CEPI) |
| 11:50 – 12:15 | The Moderna mRNA Vaccine Platform to Address SARS-CoV-2 | Jackie Miller (Moderna) |
| 12:15 – 12:40 | BioNTech’s SARS-CoV-2 mRNA vaccines | Ugur Sahin (BioNTech) |
| 12:40 – 13:05 | Development of SARS-CoV-2 vaccine based on CureVac’s mRNA technology | Lidia Oostvogels (CureVac) |
| 13:05 – 13:15 | Break | |
| 13:15 – 13:40 | Development of a self-amplifying RNA SARS-CoV-2 vaccine candidate | Robin Shattock (Imperial College, London) |
| 13:40 – 14:05 | LUNAR®-COV19: The Arcturus Therapeutics SARS-CoV-2 mRNA Vaccine Candidate | Sean Sullivan (Arcturus Therapeutics) |
| 14:05 – 14:25 | The Innovative Medicines Initiative: Responding to COVID-19 through a public-private partnership | Pierre Meulien (Innovative Medicines Initiative) |
| 14:25 – 14:45 | Break | |
| 14:45 – 16:15 | Session VIII: Regulatory Considerations | Chair: Charbel Haber |
| 14:45 – 15:00 | The Regulatory Landscape for mRNA Vaccines: A U.S. Perspective | Norman W. Baylor (Biologics Consulting) |
| 15:00 – 15:15 | Regulatory Considerations Specific to mRNA-based SARS-CoV-2 Vaccines | Michael Pfleiderer (Biopharma Excellence) |
| 15:15 – 16:15 | Round Table Discussion with Drs. Baylor and Pfleiderer, and Regulatory Heads Charbel Haber from Moderna, John Talian from CureVac and Andreas Kuhn from BioNTech | Norman W. Baylor (Biologics Consulting), Michael Pfleiderer (Biopharma Excellence), John Talian (CureVac), Charbel Haber (Moderna), Andreas Kuhn (BionTech) |
| 16:15 – 16:30 | Closing and passing of the baton | Organizing Committee |
Click here for our privacy policy.
